✳️ Kadena 200% Short-Term Move (EMA300 Scientific Proof)
Our scientific proof comes in as the Exponential Moving Average of 300 periods (EMA300). As soon as KDABTC moved above this level, scientific wisdom dictates that the bias is bullish.
This is not a "subjective" statement, there is no subject here. This is a fact based purely on the evidence coming from the chart; 100% objective.
We did a double-blind, randomized, placebo controlled, peer-reviewed trial that shows when a Cryptocurrency trading pair moves above EMA300, coming from a low point, this indicates potential for higher prices. Never mind that the peer review process is done by ourselves, that the placebo works better than drugs and that countless unknown phenomena continue to happen and exist and work even with no studies involved; Kadena is set to move higher because I say so.
Namaste.
This is not a "subjective" statement, there is no subject here. This is a fact based purely on the evidence coming from the chart; 100% objective.
We did a double-blind, randomized, placebo controlled, peer-reviewed trial that shows when a Cryptocurrency trading pair moves above EMA300, coming from a low point, this indicates potential for higher prices. Never mind that the peer review process is done by ourselves, that the placebo works better than drugs and that countless unknown phenomena continue to happen and exist and work even with no studies involved; Kadena is set to move higher because I say so.
Namaste.
🔝 Daily Cryptocurrency Technical Analysis
followalan.com
🔥 PREMIUM Trade-Numbers (6-In-1 Offer Now Live!)
lamatrades.com (Since 2017)
🚨 Free PREMIUM Trade-Numbers
alansantanatrades.com
followalan.com
🔥 PREMIUM Trade-Numbers (6-In-1 Offer Now Live!)
lamatrades.com (Since 2017)
🚨 Free PREMIUM Trade-Numbers
alansantanatrades.com
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.